In a regulatory filing the company said that the board of directors of the company, at its meeting held on Tuesday has approved the buy-back of its equity shares from the open market at a maximum price of Rs 425 per share for an aggregate maximum amount of up to Rs 1,700 crore.
"At the maximum buy-back size and the maximum buy-back price, the indicative maximum number of equity shares to be bought back under the buy-back would be four crore equity shares which represents 1.67 per cent of the total number of equity shares of the company," the filing said.
However, the actual number of equity shares to be bought back during the buy-back will depend upon the actual price paid (excluding the transaction costs) for the equity shares bought back and the aggregate actual amount utilised in the buy-back, the filing said.
The filing further added that the public announcement setting out the process, timelines and other requisite details will be released in due course in accordance with the buy-back regulations.
This represents 9.83 per cent of the total paid-up equity share capital of the company, it added.
Shares of Sun Pharmaceutical Industries were trading at Rs 380.70 per scrip on BSE, up 3.23 per cent from its previous close. AKT AKT DRRDRR